Persistence of expression of the TMPRSS2:ERG fusion gene after pre-surgery androgen ablation may be associated with early prostate specific antigen relapse of prostate cancer: Preliminary results Journal Article


Authors: Bonaccorsi, L.; Nesi, G.; Nuti, F.; Paglierani, M.; Krausz, C.; Masieri, L.; Serni, S.; Proietti-Pannunzi, L.; Fang, Y.; Jhanwar, S. C.; Orlando, C.; Carini, M.; Forti, G.; Baldi, E.; Luzzatto, L.
Article Title: Persistence of expression of the TMPRSS2:ERG fusion gene after pre-surgery androgen ablation may be associated with early prostate specific antigen relapse of prostate cancer: Preliminary results
Abstract: Background: The recently identified TMPRSS2:ERG fusion gene is a candidate oncogene for prostate cancer (PCa). Subjects and methods: We have tested for the presence of this gene in tumor samples from 84 patients who had radical prostatectomy in 1998-2000. Sixty patients (group A) had surgery only; 24 patients (group B) received androgen ablation therapy for 3 months before surgery. The occurrence of the rearrangement was evaluated by RT-PCR and by fluorescent in situ hybridization analysis. Results: A TMPRSS2:ERG fusion gene was present and expressed, as demonstrated by RT-PCR, in 84% of patients in group A and in 54% of patients in group B (p=0.01). The presence of TMPRSS2:ERG transcripts and the levels of ERG RNA, measured by quantitative Real Time-PCR, did not correlate significantly with clinical and pathologic characteristics of the tumors. In patients of group A, but not in those of group B, ERG expression showed a negative correlation with the Gleason score (p=0.0001). Histochemical analysis showed that ERG expression is limited to tumor cells, and in group A patients (but not in group B patients) it is limited to those glands that express TMPRSS2:ERG. Conclusion: The lower proportion of patients expressing TMPRSS2:ERG in group B suggests that androgen ablation inhibits the expression of TMPRSS2:ERG. Moreover, in group B, but not in group A, patients with expression of the fusion gene had earlier prostate specific antigen recurrence (p=0.007). Although preliminary, the data indicate that tumors in which pre-surgery androgen ablation fails to suppress expression of the fusion gene have a higher risk of recurrence. ©2009, Editrice Kurtis.
Keywords: controlled study; human tissue; protein expression; treatment outcome; aged; middle aged; human cell; major clinical study; prostate specific antigen; animals; reverse transcription polymerase chain reaction; gene expression; recurrence; cancer therapy; prostate cancer; kaplan-meiers estimate; prostate-specific antigen; prostatic neoplasms; rna; correlation analysis; fluorescence in situ hybridization; preoperative period; gene rearrangement; prostatectomy; quantitative analysis; gene fusion; psa recurrence; tmprss2:erg; transcription factor erg; androgen ablation; fusion gene; scoring system; tmprss2:erg fusion gene; ablation techniques; androgen antagonists; oncogene proteins, fusion
Journal Title: Journal of Endocrinological Investigation
Volume: 32
Issue: 7
ISSN: 0391-4097
Publisher: Springer  
Date Published: 2009-07-01
Start Page: 590
End Page: 596
Language: English
DOI: 10.3275/6258
PUBMED: 19494719
PROVIDER: scopus
DOI/URL:
Notes: --- - "Cited By (since 1996): 4" - "Export Date: 30 November 2010" - "CODEN: JEIND" - "Source: Scopus"
Altmetric Score
MSK Authors
  1. Suresh C Jhanwar
    217 Jhanwar
  2. Yuqiang Fang
    20 Fang